Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies

References

• Marrero DG. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. Clin Cornerstone 2008;9:63-70
   Google Scholar
• Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J 2007;100:164-74
   PubMed Web of Science ®Google Scholar
• Goodall G, Sarpong EM, Hayes C, et al. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord 2009;9:19
   PubMed Web of Science ®Google Scholar
• Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008;10:247-56
   PubMed Web of Science ®Google Scholar
• Cuddihy RM, Borgman SK. Considerations for diabetes: treatment with insulin pen devices. Am J Ther 2011: published online July 15 2011, doi: 10.1097/MJT.0b013e318217a5e3
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care 2012;35(1 Suppl):S11-63
   Google Scholar
• Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
   PubMedGoogle Scholar
• Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63
   PubMedGoogle Scholar
• Quilliam BJ, Simeone JC, Ozbay AB, et al. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care 2011;17:673-80
   PubMed Web of Science ®Google Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
   PubMed Web of Science ®Google Scholar
• Bron M, Marynchenko M, Yang H, et al. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012;124:124-32
   PubMed Web of Science ®Google Scholar
• Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
   PubMedGoogle Scholar
• Dailey G, Strange P. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. Am J Manag Care 2008;14:25-30
   PubMed Web of Science ®Google Scholar
• Davis S, Wei W, Garg S. Clinical impact of initiating insulin glargine with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-52
   PubMed Web of Science ®Google Scholar
• Xie L, Wei W, Pan C, et al. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther 2011;28:1000-11
   PubMed Web of Science ®Google Scholar
• Du J, Wei W, Xie L, et al. Real-world outcomes of initiating two different basal insulin therapies via disposable pens among patients with type 2 diabetes in US employer-sponsored health plans. Value Health 2011;14:A476
   Google Scholar
• Garg SK, Wei W, Cao Z, et al. Clinical and economic outcomes among employees or their dependents with type 2 diabetes initiating insulin glargine via disposable pen or vial. J Gen Intern Med 2012;27(2 Suppl):S99-574
   Google Scholar
• Lin J, Ling J, Wei W, et al. Outcomes of initiating insulin glargine therapy with disposable pen or vial among patients with type 2 diabetes in a US managed care health plan. J Diabetes Sci Technol 2012;6:462-5, A1-A202
   Google Scholar
• Baser O, Wei W, Baser E, et al. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. J Med Econ 2011;14:673-80
   PubMedGoogle Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Zhao Y, Campbell CR, Fonseca V, et al. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-32
   PubMed Web of Science ®Google Scholar
• Simeone JC, Quilliam BJ. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database. Ann Pharmacother 2012;46:157-68
   PubMed Web of Science ®Google Scholar
• Williams SA, Shi L, Brenneman SK, et al. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications 2012;26:399-406
   PubMed Web of Science ®Google Scholar
• Levy P. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad Med 2009;121:7-12
   PubMed Web of Science ®Google Scholar
• Ginde AA, Blanc PG, Lieberman RM, et al. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008;8:4
   PubMedGoogle Scholar
• Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, et al. A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. Health Qual Life Outcomes 2011;9:83
   PubMedGoogle Scholar
• Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ 2002;28:52-60
   PubMed Web of Science ®Google Scholar